NBIX
Neurocrine Biosciences Inc
143.20$
+1.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 57.9% | 49.4% | 51.8% | 50.5% | 53.1% | 46.4% | 44.4% | 45.0% | 50.6% | 54.5% | 49.7% | 30.6% | |
| 10.3% | 7.7% | 11.4% | 4.2% | 9.9% | 6.3% | 5.3% | 6.8% | 8.0% | 15.4% | 5.4% | 6.2% | |
| 38.4% | 31.7% | 34.9% | 31.4% | 34.7% | 28.9% | 25.6% | 25.1% | 26.1% | 32.0% | 26.8% | 7.3% | |
| 14.7% | 13.5% | 13.0% | 14.2% | 13.6% | 12.9% | 14.0% | 15.3% | 17.1% | 14.8% | 15.7% | 16.6% | |
| 1.0% | 1.2% | 1.1% | 1.3% | 1.3% | 1.5% | 1.6% | 1.5% | 1.6% | 1.5% | 1.3% | 1.9% | |
| – | 0.2% | – | 0.2% | 0.2% | 0.1% | – | – | – | – | – | 9.3% | |
| 1.2% | 1.1% | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% | 0.8% | – | – | 41.5% | |
| 29.7% | 31.4% | 31.3% | 24.1% | 23.1% | 30.4% | 31.2% | 30.7% | 29.6% | 29.8% | 30.5% | 31.1% | |
| 24.3% | 20.1% | 20.5% | 12.1% | 12.2% | 13.7% | 14.2% | 14.0% | 15.0% | 16.1% | 17.0% | 16.3% | |
| 6.6% | 5.2% | 7.5% | 1.1% | 1.0% | – | – | – | 1.2% | – | – | – | |
| 3.3% | 4.1% | 2.5% | 3.2% | 2.7% | 2.7% | 3.0% | 2.7% | 2.8% | 2.3% | 2.4% | 2.6% | |
| 70.3% | 68.6% | 68.7% | 75.9% | 76.9% | 69.6% | 68.8% | 69.3% | 70.4% | 70.2% | 69.5% | 68.9% | |
| -10.7% | -4.8% | -3.3% | -1.5% | 2.3% | 0.8% | -0.1% | 2.2% | 6.9% | 9.7% | 12.0% | 13.5% | |
| 3.5% | 3.1% | 3.0% | 3.1% | 3.0% | 2.8% | 2.8% | 2.6% | 2.4% | 2.2% | 2.1% | 1.9% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.